Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196284 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03196284 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 26 participants.
The verdict
NCT03196284, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.
Interventions
- DRUG Concizumab
- DRUG Eptacog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196284
The ClinicalTrials.gov registry entry for NCT03196284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Concizumab is the first listed.
NCT03196284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03196284 about?
NCT03196284 is a clinical study titled "A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors". This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.
What is the current status of trial NCT03196284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-08-10. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03196284?
The interventions under investigation include: Concizumab (DRUG), Eptacog alfa (DRUG).
Who is sponsoring clinical trial NCT03196284?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.